LY-2623091

DB15367InvestigationalSmall molecule

LY-2623091 is under investigation in clinical trial NCT02194465 (A Study of LY2623091 in Participants With High Blood Pressure).

Chemical structure of LY-2623091
Mechanism
Curator reviewed
Formula / weight
C30H30FN5O3 · 527.6 g/mol (avg)
Code names
LY-2623091

Resolves to

Compound
UNII6FHZ595FNMCAS1162264-07-4ChEMBLCHEMBL4088896
Structure
InChIKeyYPCLDHGBEKZGEB-RUDKWAFVSA-NSMILESC[C@H](CN1CCOCC1)N1C(NC(N)=O)=NC2=C1C=CC(\C=C1/C3=CC=CC=C3COC3=CC(F)=CC=C13)=C2
Targets
P08235NR3C2

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
4Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with LY-2623091, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In